Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).
Sunakawa Y, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Takahashi M, Matsuyama J, Yabusaki H, Makiyama A, Suzuki T, Tsuda M, Yasui H, Hihara J, Takeno A, Inoue E, Ichikawa W, Fujii M. Sunakawa Y, et al. Among authors: yabusaki h. Oncologist. 2024 Apr 6:oyae056. doi: 10.1093/oncolo/oyae056. Online ahead of print. Oncologist. 2024. PMID: 38581687 Free article.
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K, Tsuburaya A, Yoshikawa T, Takahashi M, Tanabe K, Yamaguchi K, Yoshino S, Namikawa T, Aoyama T, Rino Y, Kawada J, Tsuji A, Taira K, Kimura Y, Kodera Y, Hirashima Y, Yabusaki H, Hirabayashi N, Fujitani K, Miyashita Y, Morita S, Sakamoto J. Nishikawa K, et al. Among authors: yabusaki h. Gastric Cancer. 2018 Sep;21(5):811-818. doi: 10.1007/s10120-018-0815-0. Epub 2018 Feb 27. Gastric Cancer. 2018. PMID: 29488122 Clinical Trial.
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Yoshikawa T, et al. Among authors: yabusaki h. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22. Lancet Gastroenterol Hepatol. 2019. PMID: 30679107 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: yabusaki h. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.
Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito S, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Lee SW, Takagane A, Yabusaki H, Hihara J, Boku N, Sano T, Sasako M. Iwasaki Y, et al. Among authors: yabusaki h. Gastric Cancer. 2021 Mar;24(2):492-502. doi: 10.1007/s10120-020-01136-7. Epub 2020 Nov 16. Gastric Cancer. 2021. PMID: 33200303 Clinical Trial.
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).
Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. Kawakami H, et al. Among authors: yabusaki h. Cancers (Basel). 2021 Feb 15;13(4):805. doi: 10.3390/cancers13040805. Cancers (Basel). 2021. PMID: 33671871 Free PMC article.
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Takahashi Y, Sunakawa Y, Inoue E, Kawabata R, Ishiguro A, Kito Y, Akamaru Y, Takahashi M, Yabusaki H, Matsuyama J, Makiyama A, Tsuda M, Suzuki T, Yasui H, Matoba R, Kawakami H, Nakajima TE, Muro K, Ichikawa W, Fujii M. Takahashi Y, et al. Among authors: yabusaki h. Gastric Cancer. 2022 Jan;25(1):235-244. doi: 10.1007/s10120-021-01237-x. Epub 2021 Aug 24. Gastric Cancer. 2022. PMID: 34427838
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.
Chin K, Takahari D, Kawabata R, Hosaka H, Saitou SO, Shiraishi T, Yabusaki H, Goto M, Nakamura M, Imamura H, Shindo Y, Nagashima F, Ichikawa W, Saotome T, Yamamoto W, Ishizuka N, Yamaguchi K. Chin K, et al. Among authors: yabusaki h. Anticancer Res. 2022 May;42(5):2683-2687. doi: 10.21873/anticanres.15746. Anticancer Res. 2022. PMID: 35489762 Clinical Trial.
122 results